Bank of America Corp DE Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY

Key Points

• Bank of America initiated a position in ARS Pharmaceuticals during the second quarter, purchasing 463,256 shares valued at approximately $3.7 million, or about 0.47% of the company. Institutional investors collectively own 68.16% of SPRY.
• ARS Pharmaceuticals faces a securities class-action lawsuit alleging investors were misled about the timing of expanded CVS Caremark coverage for neffy. The company’s shares fell 23.9% on June 24 after the coverage expectations changed, and investors face an October 5, 2026 lead-plaintiff deadline.
• SPRY opened at $4.40, near its 52-week low of $4.00, while analysts maintain a “Moderate Buy” consensus with a $25 target price. However, the company reported a quarterly EPS loss of $0.63, missing estimates, despite revenue of $33.66 million exceeding expectations.

Bank of America Corp DE bought a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 463,256 shares of the company's stock, valued at approximately $3,711,000. Bank of America Corp DE owned about 0.47% of ARS Pharmaceuticals as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Bessemer Group Inc. boosted its position in shares of ARS Pharmaceuticals by 3,102.1% in the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company's stock valued at $61,000 after acquiring an additional 7,290 shares during the period. Alpine Woods Capital Investors LLC bought a new position in ARS Pharmaceuticals during the first quarter worth $80,000. Foster & Motley Inc. bought a new position in ARS Pharmaceuticals during the second quarter worth $118,000. ProShare Advisors LLC raised its stake in ARS Pharmaceuticals by 11.3% during the 4th quarter. ProShare Advisors LLC now owns 15,139 shares of the company's stock valued at $176,000 after purchasing an additional 1,532 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new position in ARS Pharmaceuticals during the 1st quarter valued at $128,000. 68.16% of the stock is owned by institutional investors.

ARS Pharmaceuticals News Roundup

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms announced that a federal securities class action has been filed against ARS Pharmaceuticals and certain executives, including Chief Commercial Officer Eric Karas. The lawsuit alleges investors were misled about the timing of expanded CVS Caremark coverage for neffy, ARS’s epinephrine nasal spray. The allegations have not been proven. SueWallSt investor alert
• Negative Sentiment: The complaints relate to a reported single-session decline of 23.9% in SPRY shares on June 24, 2026, after investors allegedly learned that expanded CVS Caremark coverage for neffy would not occur as previously expected. This raises potential financial, legal and disclosure risks for the company. Levi & Korsinsky shareholder alert
• Negative Sentiment: Investors who purchased ARS securities between March 9 and June 24, 2026, are being encouraged to seek lead-plaintiff status by October 5, 2026. The repeated notices from Kaplan Fox, Pomerantz, Rosen, Faruqi & Faruqi and other firms increase visibility around the dispute, potentially weighing on investor sentiment and adding uncertainty. Kaplan Fox class-action notice

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on SPRY shares. Leerink Partners set a $15.00 target price on ARS Pharmaceuticals in a research note on Tuesday, September 8th. Weiss Ratings lowered shares of ARS Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a report on Monday, August 17th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $25.00.

ARS Pharmaceuticals Stock Performance

Shares of NASDAQ:SPRY opened at $4.40 on Wednesday. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.48 and a quick ratio of 3.28. The business's fifty day moving average price is $5.37 and its two-hundred day moving average price is $7.33. ARS Pharmaceuticals, Inc. has a fifty-two week low of $4.00 and a fifty-two week high of $13.15. The stock has a market capitalization of $437.58 million, a price-to-earnings ratio of -2.02 and a beta of 1.05.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.15). The firm had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. ARS Pharmaceuticals had a negative return on equity of 256.67% and a negative net margin of 184.24%. As a group, analysts predict that ARS Pharmaceuticals, Inc. will post -1.9 EPS for the current fiscal year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company's lead product is neffy, an epinephrine nasal spray designed to provide emergency treatment for allergic reactions, including anaphylaxis, without requiring an injection.

The U.S. Food and Drug Administration approved neffy in 2024 for adults and children who weigh at least 30 kilograms. The product is intended for use when epinephrine is needed and is designed to address barriers associated with injectable epinephrine, such as needle fear, difficulty with administration, and hesitation to use an auto-injector.

ARS Pharmaceuticals was founded in 2015 and is headquartered in San Mateo, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.